title: [Weekly administration of gemcitabine and docetaxel combinations in the treatment of advanced non-small cell lung cancer].
abstract: BACKGROUND
  To evaluate the efficacy and side effects of weekly administration of gemcitabine combined with docetaxel in the treatment of advanced non-small cell lung cancer.
  
  
  METHODS
  Twenty-six patients with advanced non-small cell lung cancer, with or without prior chemotherapy, were entered into this study. Gemcitabine and docetaxel were administrated weekly for 3 consecutive weeks, followed by 1 week rest. Gemcitabine was given as 800-1 200 mg/m² by intravenous infusion on days 1, 8, 15; while docetaxel was 35 mg/m² intravenously on the same days as gemcitabine. The efficacy including response rate and median survival duration and toxicity were observed.
  
  
  RESULTS
  Of the 26 patients, one achieved complete response (CR), and 6 achieved partial response (PR), with an overall response rate of 27%. The median survival duration was 9.5 months and 1-year survival rate was 38% (10/26). The main toxicities were neutropenia and thrombocytopenia. One patient died from allergic shock.
  
  
  CONCLUSIONS
  The combination of docetaxel and gemcitabine is effective and well-tolerated in the treatment of advanced NSCLC.
authors.affiliation: Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, P.R.China.
authors.forename: Junling
authors.initials: J
authors.lastname: Li
authors.forename: Yilong
authors.initials: Y
authors.lastname: Wu
authors.forename: Longyun
authors.initials: L
authors.lastname: Li
authors.forename: Lijia
authors.initials: L
authors.lastname: Gu
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Jinwan
authors.initials: J
authors.lastname: Wang
authors.forename: Xiangru
authors.initials: X
authors.lastname: Zhang
authors.forename: Yan
authors.initials: Y
authors.lastname: Sun